DK2266558T3 - Behandling af neuropatiske smerter med receptor-antagonist: n-methyl-d-aspartat (nmda) - Google Patents
Behandling af neuropatiske smerter med receptor-antagonist: n-methyl-d-aspartat (nmda) Download PDFInfo
- Publication number
- DK2266558T3 DK2266558T3 DK10183424.0T DK10183424T DK2266558T3 DK 2266558 T3 DK2266558 T3 DK 2266558T3 DK 10183424 T DK10183424 T DK 10183424T DK 2266558 T3 DK2266558 T3 DK 2266558T3
- Authority
- DK
- Denmark
- Prior art keywords
- dextromethorphan
- pain
- dose
- treatment
- gabapentin
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 68
- 208000004296 neuralgia Diseases 0.000 title claims description 50
- 208000021722 neuropathic pain Diseases 0.000 title claims description 50
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title description 6
- 229940044551 receptor antagonist Drugs 0.000 title description 4
- 239000002464 receptor antagonist Substances 0.000 title description 4
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 105
- 229960001985 dextromethorphan Drugs 0.000 claims description 105
- 208000020431 spinal cord injury Diseases 0.000 claims description 46
- 230000000202 analgesic effect Effects 0.000 claims description 38
- 230000001684 chronic effect Effects 0.000 claims description 25
- 210000000278 spinal cord Anatomy 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 20
- 230000006378 damage Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 230000007246 mechanism Effects 0.000 claims description 9
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002831 pharmacologic agent Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 25
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 119
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 111
- 230000036407 pain Effects 0.000 description 111
- 229960002870 gabapentin Drugs 0.000 description 58
- 239000000902 placebo Substances 0.000 description 41
- 229940068196 placebo Drugs 0.000 description 41
- 230000000694 effects Effects 0.000 description 33
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 27
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 27
- 208000004454 Hyperalgesia Diseases 0.000 description 26
- 206010053552 allodynia Diseases 0.000 description 16
- 208000014674 injury Diseases 0.000 description 16
- 230000000763 evoking effect Effects 0.000 description 14
- 208000035154 Hyperesthesia Diseases 0.000 description 10
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 10
- 229960003299 ketamine Drugs 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 230000002269 spontaneous effect Effects 0.000 description 9
- 230000008733 trauma Effects 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 230000036592 analgesia Effects 0.000 description 7
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 206010033892 Paraplegia Diseases 0.000 description 5
- 208000032140 Sleepiness Diseases 0.000 description 5
- 206010041349 Somnolence Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 208000002173 dizziness Diseases 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000003190 augmentative effect Effects 0.000 description 4
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010042928 Syringomyelia Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000000472 traumatic effect Effects 0.000 description 3
- 231100000216 vascular lesion Toxicity 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 amantadine Drugs 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- -1 p=0.03 Chemical compound 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002385 psychotomimetic effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 229950000659 remacemide Drugs 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 229940127558 rescue medication Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (6)
1. Dextromethorphan til anvendelse ved behandling af central kronisk neuropatisk smerte i mennesker forarsaget af beskadigelse af rygmarven, og hvor dextromethor- 5 phan administreret indgives ved hjaelp af titreret administrering.
2. Dextromethorphan til anvendelse ifplge krav 1, hvor den titrerede dosis omfatter en fprste dosis andragende 120 mg/dag af dextromethorphan efterfulgt af i det mindste en hojere dosis. 10
3. Dextromethorphan til anvendelse ifolge ki'av 2, hvor den i det mindste en hojere dosis, i det mindste en dosis, som er hojere, er hojere med et inkrement andragende 60 mg/dag af dextromethorphan.
4. Dextromethorphan til anvendelse ifolge et hvilket som heist af de forudgaende krav ved fremstilling af et medikament som ifolge ki'av 2, hvor, hvor den titrerede dosis omfatter en I'orste dosis andragende 120 mg/dag af dextromethorphan efterfulgt af et flertal af hojere doser, som foroges inkrementalt med dextromethorphan andragende 60 mg/dag dextromethorphan. 20
5. Dextromethorphan til anvendelse ifolge et hvilket som heist af de forudgaende ki'av, og som yderligere omfatter administrering af et andet pharmakologisk middel, som indvirker ved hjaelp af en anderledes pharmakologisk mekanisme.
6. Analgesisk sammensaetning omfattende dextromethorphan til anvendelse ved be handling af kronisk central neuropatisk smerte forarsaget som lolge af rygmarvsskade i mennesker, hvor sammensaetningen er analgesisk derved, at der afgives en dosis dextromethorphan aekvivalent med et inkrement andragende 60 mg/dag.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10183424.0A EP2266558B1 (en) | 2001-06-07 | 2001-06-07 | Treatment of neuropathic pain with the N-methyl-D-aspartate (NMDA) receptor antagonist dextromethorphan |
| EP01942162A EP1395289B1 (en) | 2001-06-07 | 2001-06-07 | Treatment of neuropathic pain with a n-methyl-d-aspartate (nmda) receptor antagonists |
| PCT/US2001/018723 WO2002100434A1 (en) | 2001-06-07 | 2001-06-07 | Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2266558T3 true DK2266558T3 (da) | 2017-07-31 |
Family
ID=21742637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01942162.7T DK1395289T3 (da) | 2001-06-07 | 2001-06-07 | Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist |
| DK10183424.0T DK2266558T3 (da) | 2001-06-07 | 2001-06-07 | Behandling af neuropatiske smerter med receptor-antagonist: n-methyl-d-aspartat (nmda) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01942162.7T DK1395289T3 (da) | 2001-06-07 | 2001-06-07 | Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8309570B2 (da) |
| EP (3) | EP2266558B1 (da) |
| AT (1) | ATE491474T1 (da) |
| CA (1) | CA2449987C (da) |
| CY (2) | CY1111900T1 (da) |
| DE (1) | DE60143671D1 (da) |
| DK (2) | DK1395289T3 (da) |
| ES (2) | ES2632544T3 (da) |
| PT (1) | PT2266558T (da) |
| WO (1) | WO2002100434A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2266558T (pt) | 2001-06-07 | 2017-07-21 | Analgesic Neuropharmaceuticals Llc | Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano |
| FR2980973B1 (fr) * | 2011-10-11 | 2013-11-15 | Univ Clermont Auvergne | Composition pour le traitement prophylactique de la douleur neuropathique. |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| WO2018229241A1 (en) * | 2017-06-16 | 2018-12-20 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Means and methods for treating neuropathic pain |
| MX2022008628A (es) | 2020-01-13 | 2022-09-26 | Astromedical Biotechnology Ltd | Uso de ketamina en el tratamiento de caquexia. |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4316888A (en) | 1980-04-15 | 1982-02-23 | Nelson Research & Development Co. | Method and composition of reducing pain |
| US4446140A (en) | 1981-12-10 | 1984-05-01 | Nelson Research & Development Company | Method and composition for treating mouth pain |
| US5629307A (en) * | 1989-10-20 | 1997-05-13 | Olney; John W. | Use of ibogaine in reducing excitotoxic brain damage |
| US5164398A (en) | 1991-04-01 | 1992-11-17 | Merck & Co., Inc. | Ibuprofen-antitussive combinations |
| US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
| CA2115792C (en) * | 1993-03-05 | 2005-11-01 | David J. Mayer | Method for the treatment of pain |
| US5834479A (en) | 1993-03-05 | 1998-11-10 | Mayer; David J. | Method and composition for alleviating pain |
| ES2268686T3 (es) | 1994-09-22 | 2007-03-16 | Richard Alan Smith | Combinacion de dextrometorfano con quinidina o sulfato de quinina para tratar diversos trastornos de dificil cura. |
| US5840731A (en) | 1995-08-02 | 1998-11-24 | Virginia Commonwealth University | Pain-alleviating drug composition and method for alleviating pain |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| CA2264182A1 (en) | 1996-08-23 | 1998-02-26 | Algos Pharmaceutical Corporation | Anticonvulsant containing composition for treating neuropathic pain |
| US5891885A (en) | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| US5919826A (en) | 1996-10-24 | 1999-07-06 | Algos Pharmaceutical Corporation | Method of alleviating pain |
| US6284794B1 (en) | 1996-11-05 | 2001-09-04 | Head Explorer Aps | Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase |
| US5801188A (en) * | 1997-01-08 | 1998-09-01 | Medtronic Inc. | Clonidine therapy enhancement |
| AU7472898A (en) | 1997-05-07 | 1998-11-27 | Algos Pharmaceutical Corporation | Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain |
| WO1998050075A1 (en) | 1997-05-07 | 1998-11-12 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| AU7696098A (en) | 1997-08-11 | 1999-03-01 | Algos Pharmaceutical Corporation | Substance p inhibitors in combination with nmda-blockers for treating pain |
| WO1999008669A1 (en) * | 1997-08-15 | 1999-02-25 | Carolyn Ann Fairbanks | Agmatine as a treatment for neuropathic pain |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| FR2772271B1 (fr) | 1997-12-11 | 2000-09-01 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| EP1068568A4 (en) * | 1998-04-03 | 2004-10-27 | Triangle Pharmaceuticals Inc | SYSTEMS, METHODS, AND COMPUTER PROGRAM PRODUCTS TO GUIDE THE SELECTION OF THERAPEUTIC SCHEMES $ i () |
| US6054451A (en) | 1998-04-21 | 2000-04-25 | Algos Pharmaceutical Corporation | Analgesic composition and method for alleviating pain |
| ES2198196B2 (es) | 1998-07-16 | 2006-04-01 | Memorial Sloan-Kettering Cancer Center | Composiciones topicas que comprenden un analgesico opioide y un antagonista de nmda. |
| US20010007872A1 (en) * | 1998-10-01 | 2001-07-12 | Frank S. Menniti | Method of treating acute, chronic and/or neuropathic pain |
| EP1146905A1 (en) | 1998-11-12 | 2001-10-24 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with nmda-blockers for treating pain |
| GB9901691D0 (en) * | 1999-01-26 | 1999-03-17 | Cerebrus Ltd | Chemical compounds |
| AU2319100A (en) * | 1999-01-28 | 2000-08-18 | Nippon Shinyaku Co. Ltd. | Amide derivatives and drug compositions |
| US6500418B1 (en) * | 1999-02-12 | 2002-12-31 | The Washington University | Stimulating neutrophil function to treat inflammatory bowel disease |
| GB9904163D0 (en) * | 1999-02-23 | 1999-04-14 | Bioglan Lab Ltd | Pharmaceutical compositions |
| EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| US6451857B1 (en) | 1999-03-10 | 2002-09-17 | Warner-Lambert Company | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| CA2377937A1 (en) * | 1999-07-15 | 2001-01-25 | Mcgill University | Oligoneucleotides for metabotropic glutamate receptor type 1 (mglur1) |
| US6664283B1 (en) * | 1999-08-02 | 2003-12-16 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceuticals for neurogenic pain |
| ES2308990T3 (es) | 1999-08-24 | 2008-12-16 | Toray Industries, Inc. | Remedios para el dolor neuropatico y modelos animales de dolor neuropatico. |
| US6677452B1 (en) | 1999-09-30 | 2004-01-13 | Lion Bioscience Ag | Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof |
| DE60142692D1 (de) | 2000-02-24 | 2010-09-09 | Xenon Genetics Inc | Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| US6825203B2 (en) | 2000-04-28 | 2004-11-30 | Memorial Sloan-Kettering Cancer Center | Topical anesthetic/opioid formulations and uses thereof |
| AU2001280438A1 (en) * | 2000-07-27 | 2002-02-13 | Eli Lilly And Company | Substituted heterocyclic amides |
| US7685005B2 (en) * | 2000-08-29 | 2010-03-23 | Medtronic, Inc. | Medical device systems implemented network scheme for remote patient management |
| ATE402262T1 (de) | 2000-09-26 | 2008-08-15 | Xenon Pharmaceuticals Inc | Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden |
| PT2266558T (pt) | 2001-06-07 | 2017-07-21 | Analgesic Neuropharmaceuticals Llc | Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano |
| WO2002102778A1 (fr) * | 2001-06-15 | 2002-12-27 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de phenylpyridinecarbonylpiperazine |
| JPWO2003037862A1 (ja) * | 2001-10-30 | 2005-02-17 | 日本新薬株式会社 | アミド誘導体及び医薬 |
| US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| EP1456175A1 (en) * | 2001-12-07 | 2004-09-15 | Eli Lilly And Company | Substituted heterocyclic carboxamides with antithrombotic activity |
| US20060167032A1 (en) | 2002-01-16 | 2006-07-27 | Galer Bradley S | Pharmaceutical composition and method for treating disorders of the central nervous system |
| WO2004010927A2 (en) * | 2002-07-25 | 2004-02-05 | Wisconsin Alumni Research Foundation | Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes |
| AU2003270393B2 (en) | 2002-09-09 | 2008-03-20 | Endo Pharmaceuticals Inc. | Combined immediate release and extended relase analgesic composition |
| US7256200B2 (en) | 2003-02-10 | 2007-08-14 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Method and composition for potentiating an oplate analgesic |
| US20060178354A1 (en) | 2003-02-27 | 2006-08-10 | Lucas John M | Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof |
| HUP0300929A3 (en) | 2003-04-09 | 2005-06-28 | Richter Gedeon Vegyeszet | Analgetic and/or muscle relaxant pharmaceutical composition |
| CA2522471A1 (en) | 2003-04-14 | 2004-10-28 | Pain Therapeutics, Inc. | Methods for the treatment of pain comprising opioid antagonists |
| US7404970B2 (en) | 2004-04-13 | 2008-07-29 | Konec, Inc. | Pain relief composition, method to form same, and method to use same |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| US20060052370A1 (en) | 2004-08-24 | 2006-03-09 | Meyerson Laurence R | Methods and compositions for treating nociceptive pain |
| EP1799264A2 (en) | 2004-10-08 | 2007-06-27 | Neuromolecular Pharmaceuticals Inc | Methods and compositions for treating migraine pain |
-
2001
- 2001-06-07 PT PT101834240T patent/PT2266558T/pt unknown
- 2001-06-07 ES ES10183424.0T patent/ES2632544T3/es not_active Expired - Lifetime
- 2001-06-07 WO PCT/US2001/018723 patent/WO2002100434A1/en active Application Filing
- 2001-06-07 EP EP10183424.0A patent/EP2266558B1/en not_active Expired - Lifetime
- 2001-06-07 EP EP01942162A patent/EP1395289B1/en not_active Expired - Lifetime
- 2001-06-07 AT AT01942162T patent/ATE491474T1/de active
- 2001-06-07 CA CA2449987A patent/CA2449987C/en not_active Expired - Lifetime
- 2001-06-07 DK DK01942162.7T patent/DK1395289T3/da active
- 2001-06-07 US US10/477,881 patent/US8309570B2/en active Active
- 2001-06-07 DE DE60143671T patent/DE60143671D1/de not_active Expired - Lifetime
- 2001-06-07 DK DK10183424.0T patent/DK2266558T3/da active
- 2001-06-07 ES ES01942162T patent/ES2357808T3/es not_active Expired - Lifetime
-
2004
- 2004-07-06 EP EP10011647A patent/EP2266566A3/en not_active Withdrawn
-
2011
- 2011-01-25 CY CY20111100080T patent/CY1111900T1/el unknown
-
2012
- 2012-10-05 US US13/646,244 patent/US20130123295A1/en not_active Abandoned
-
2017
- 2017-05-22 CY CY20171100537T patent/CY1119257T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2266566A3 (en) | 2011-01-12 |
| CY1111900T1 (el) | 2015-11-04 |
| WO2002100434A1 (en) | 2002-12-19 |
| DE60143671D1 (de) | 2011-01-27 |
| US20050009916A1 (en) | 2005-01-13 |
| ES2357808T3 (es) | 2011-04-29 |
| EP1395289B1 (en) | 2010-12-15 |
| PT2266558T (pt) | 2017-07-21 |
| CA2449987A1 (en) | 2002-12-19 |
| EP2266558B1 (en) | 2017-04-19 |
| US20130123295A1 (en) | 2013-05-16 |
| ES2632544T3 (es) | 2017-09-14 |
| EP2266566A2 (en) | 2010-12-29 |
| CY1119257T1 (el) | 2018-02-14 |
| DK1395289T3 (da) | 2011-03-28 |
| CA2449987C (en) | 2015-11-03 |
| EP1395289A1 (en) | 2004-03-10 |
| US8309570B2 (en) | 2012-11-13 |
| ATE491474T1 (de) | 2011-01-15 |
| EP2266558A3 (en) | 2011-11-23 |
| EP2266558A2 (en) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deer et al. | Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel | |
| Gilron et al. | Combination pharmacotherapy for management of chronic pain: from bench to bedside | |
| Frampton et al. | Pregabalin: in the treatment of postherpetic neuralgia | |
| Wheeler | Myofascial pain disorders: theory to therapy | |
| JP4249415B2 (ja) | Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物 | |
| Arendt-Nielsen et al. | Effects of gabapentin on experimental somatic pain and temporal summation | |
| Eisenberg et al. | Drug combinations in the treatment of neuropathic pain | |
| Lipman | Analgesic drugs for neuropathic and sympathetically maintained pain | |
| US20130123295A1 (en) | Treatment of neuropathic pain with n-methyl-d-aspartate (nmda) receptor antagonists | |
| Gajraj | Pregabalin for pain management | |
| JP6137833B2 (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| Arendt-Nielsen et al. | A translational study of the effects of ketamine and pregabalin on temporal summation of experimental pain | |
| Scheinfeld | Topical treatments of skin pain: a general review with a focus on hidradenitis suppurativa with topical agents | |
| EP0432994A2 (en) | Excitatory amino acid antagonists as anti-emetic drugs | |
| JP6768520B2 (ja) | 医療用の（ｓ）−ピルリンドールおよびその薬学的に許容可能な塩 | |
| Dong et al. | The analgesic action of topical diclofenac may be mediated through peripheral NMDA receptor antagonism | |
| EP2343976A1 (en) | Methods of using sustained release aminopyridine compositions | |
| PT1395289E (pt) | Tratamento da dor neuropática com antagonistas do receptor de n-metil-d-aspartato (nmda) | |
| KR20120050512A (ko) | 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료 | |
| Kishi et al. | Concurrent activation of hippocampal glycine and polyamine sites of the N-methyl-D-aspartate receptor synergistically reverses working memory deficits in rats | |
| JP2017101081A (ja) | 経口ｂ１２治療 | |
| CA2897624A1 (en) | Treatment of central neuropathic pain | |
| Staats et al. | Long-term intrathecal ziconotide therapy: a case study and discussion | |
| AU763273B2 (en) | Analgesic regimen | |
| Bonjardim et al. | Nociceptive behavior induced by mustard oil injection into the temporomandibular joint is blocked by a peripheral non-opioid analgesic and a central opioid analgesic |